A Phase 3 interventional study of Ravulizumab and BSC in COVID-19 Severe Pneumonia, Acute Lung Injury and Acute Respiratory Distress Syndrome, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 39 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-24.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Acute Lung Injury with a site in United States — 17 open to participants now, 19 under way, 1 of them phase 3. Acute Lung Injury · United States.
Among the 112 studies in Acute Lung Injury with a site in United States, this one is the 18th largest by enrollment of the 88 interventional ones that give a count, is one of 14 that started in 2020, is one of 11 in phase 3, and was the 76th registered.
382 studies on the registry are indexed under Acute Lung Injury; 73 are open to participants now.
Browse Acute Lung Injury studies →17 of the 112 studies in Acute Lung Injury with a site in United States are open now. Recruiting first, the newest first:
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
Prenosis, Inc. · Sites in United States
Ages 18+
Implicit Bioscience · Sites in United States
Ages 18+
HTIC, Inc · Sites in United States
Ages 18–65 · Healthy volunteers
University of Kentucky · Sites in United States
Ages 18–99 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Acute Lung Injury studies recruiting now, 25 (56%) set no upper age limit and 8 (18%) stop at 75 or younger; 6 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 42 · Phase 3 17 · Phase 4 4
First in 2001; this study’s year is marked. 14 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 202 is above the median of 60 across 227 interventional studies indexed under Acute Lung Injury.
Median enrollment 68 across the 88 interventional studies, 135 across the 22 observational. Of the 79 that completed or were terminated, 40 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 112 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
AstraZeneca has 3 studies filed under Acute Lung Injury — fewer than ten, so there is no comparison to draw.
5 of the studies in Acute Lung Injury with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07125079University of PennsylvaniaLung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy. | 2026-12-20 |
| NCT07449572HTIC, IncClinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS | 2027-01 |
| NCT06476132National Institute of Allergy and Infectious Diseases (NIAID)Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients | 2027-05-30 |
| NCT04068012Children's Hospital Los AngelesClinical Decision Support Tool in PARDS Pilot Study | 2027-07 |
| NCT05977153The University of Texas Medical Branch, GalvestonCT for Personalized Mechanical Ventilation | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 112 studies in Acute Lung Injury with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab administered in adult participants with coronavirus disease 2019 (COVID-19) severe pneumonia, acute lung injury, or acute respiratory distress syndrome. Participants were randomly assigned to receive ravulizumab in addition to best supportive care (BSC) (2/3 of the participants) or BSC alone (1/3 of the participants). BSC consisted of medical treatment and/or medical interventions per routine hospital practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Used the following medications and therapies:
Treatment with therapy in a clinical study within 30 days before randomization, or within 5 half-lives of that investigational therapy, whichever was greater. Exceptions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Ravulizumab · Other: BSC
Other: BSC
Weight-based doses of ravulizumab were administered intravenously on Days 1, 5, 10, and 15.
Also known as: Ultomiris, ALXN1210
Participants received medications, therapies, and interventions per standard hospital treatment protocols.
Survival (Based On All-Cause Mortality) in Participants in the ITT Population At Day 29
Survival (based on all-cause mortality) in Participants in the ITT Population at Day 29 was analyzed. The result for the survival was estimated survival combined over all imputations.
Time frame: Day 29
Number Of Days Free Of Mechanical Ventilation At Day 29
The number of days free of mechanical ventilation was defined as the total number of days from Day 1 to Day 29 without invasive or non-invasive mechanical ventilation.
Time frame: Day 29
Number of Days the Participants Were Alive and Not in ICU
The number of days that the participants were alive and not in the ICU from Day 1 through Day 29 are presented.
Time frame: Day 1 through Day 29
Change From Baseline In Sequential Organ Failure Assessment (SOFA) At Day 29
Baseline was defined as the last available assessment on or before Day 1 for all participants. Participants were evaluated using the SOFA score, an assessment tool that included a review of 6 organ systems: respiratory, renal, hepatic, cardiac, coagulation, and central nervous system. Each organ system was scored from 0 to 4 points using the worst value observed within the previous 24 hours. The total score ranged from 0 to 24, with a higher score indicating a worse condition.
Time frame: Baseline, Day 29
Change From Baseline In Peripheral Capillary Oxygen Saturation/Fraction Of Inspired Oxygen (SpO2/FiO2) At Day 29
Oxygenation was measured using the SpO2 and the amount of supplemental oxygen as measured by the FiO2 received by taking the ratio of these 2 measures at the same time point.
Time frame: Baseline, Day 29
Number of Days the Participants Were Alive and Not in the Hospital
The number of days that the participants were alive and not in the hospital from Day 1 through Day 29 are presented.
Time frame: Day 1 through Day 29
Estimated Number of Participants Alive At Up To Day 60 and At Up To Day 90
For this analysis, 2 participants in Group 1 (Ravulizumab + BSC) and 1 participant in Group 2 (BSC Alone) were censored at Day 90. The estimated number of participants alive for this analysis was calculated using the method of Kaplan and Meier (KM) and compared using a log-rank test stratified by intubated or not intubated on Day 1 as a sensitivity analysis. This Outcome Measure was designed to project an estimate of how many participants would be alive and not the actual number of alive participants. All-Cause Mortality data is provided in the Adverse Events Section.
Time frame: Up to Day 60 and Up to Day 90
Serum Ravulizumab Concentrations Prior to Dosing on Day 1 and Day 29
Results are reported in micrograms/milliliter (μg/mL).
Time frame: Day 1 and Day 29
Change From Baseline In Serum Free Complement Component 5 Concentrations At Day 29
Time frame: Baseline, Day 29
Change From Baseline In Terminal Complement Complex C5b-9 At Day 29
Time frame: Baseline, Day 29
| Milestone | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone |
|---|---|---|
| Started | 135 | 67 |
| Intent to treat (itt) population | 135 | 66 |
| Pharmacokinetic (pk) | 127 | 52 |
| Safety population | 127 | 67 |
| Completed | 125 | 58 |
| Not completed | 10 | 9 |
| Withdrew: Lost to follow-up | 2 | 4 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Did not meet inclusion/exclusion criteria | 2 | 0 |
| Withdrew: Not qualified due to history of anaphylaxis | 1 | 0 |
| Withdrew: Unable to provide consent | 0 | 1 |
Survival (based on all-cause mortality) in Participants in the ITT Population at Day 29 was analyzed. The result for the survival was estimated survival combined over all imputations.
| Percentage of participants | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone |
|---|---|---|
| Survival (Based On All-Cause Mortality) in Participants in the ITT Population At Day 29 | 57.6 | 59.7 |
The number of days free of mechanical ventilation was defined as the total number of days from Day 1 to Day 29 without invasive or non-invasive mechanical ventilation.
| Days | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone |
|---|---|---|
| Number Of Days Free Of Mechanical Ventilation At Day 29 | 6.79 (4.79 to 8.80) | 6.81 (4.19 to 9.43) |
The number of days that the participants were alive and not in the ICU from Day 1 through Day 29 are presented.
| Days | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone |
|---|---|---|
| Number of Days the Participants Were Alive and Not in ICU | 6.09 (4.31 to 7.87) | 6.71 (4.38 to 9.03) |
Baseline was defined as the last available assessment on or before Day 1 for all participants. Participants were evaluated using the SOFA score, an assessment tool that included a review of 6 organ systems: respiratory, renal, hepatic, cardiac, coagulation, and central nervous system. Each organ system was scored from 0 to 4 points using the worst value observed within the previous 24 hours. The total score ranged from 0 to 24, with a higher score indicating a worse condition.
| Units on a scale | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone |
|---|---|---|
| Change From Baseline In Sequential Organ Failure Assessment (SOFA) At Day 29 | -2.0 ± 6.25 | -4.5 ± 4.90 |
Oxygenation was measured using the SpO2 and the amount of supplemental oxygen as measured by the FiO2 received by taking the ratio of these 2 measures at the same time point.
| ratio | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone |
|---|---|---|
| Change From Baseline In Peripheral Capillary Oxygen Saturation/Fraction Of Inspired Oxygen (SpO2/FiO2) At Day 29 | 62.5 ± 112.43 | 134.0 ± 104.35 |
The number of days that the participants were alive and not in the hospital from Day 1 through Day 29 are presented.
| Days | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone |
|---|---|---|
| Number of Days the Participants Were Alive and Not in the Hospital | 3.02 (1.76 to 4.29) | 3.47 (1.83 to 5.12) |
For this analysis, 2 participants in Group 1 (Ravulizumab + BSC) and 1 participant in Group 2 (BSC Alone) were censored at Day 90. The estimated number of participants alive for this analysis was calculated using the method of Kaplan and Meier (KM) and compared using a log-rank test stratified by intubated or not intubated on Day 1 as a sensitivity analysis. This Outcome Measure was designed to project an estimate of how many participants would be alive and not the actual number of alive participants. All-Cause Mortality data is provided in the Adverse Events Section.
| Participants | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone |
|---|---|---|
| Day 60 | 60 | 29 |
| Day 90 | 49 | 20 |
Results are reported in micrograms/milliliter (μg/mL).
| μg/mL | Group 1 - Ravulizumab + BSC |
|---|---|
| Day 1 (predose) | 0.00 ± 0.00 |
| Day 29 (predose) | 231.35 ± 149.741 |
| μg/mL | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone |
|---|---|---|
| Change From Baseline In Serum Free Complement Component 5 Concentrations At Day 29 | -156.31 ± 61.599 | 21.79 ± 67.918 |
| ug/L | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone |
|---|---|---|
| Change From Baseline In Terminal Complement Complex C5b-9 At Day 29 | -133.23 ± 202.070 | -277.21 ± 604.742 |
Collected over Day 1 through Day 90. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 - Ravulizumab + BSC | 55/135 (40.7%) | 79/127 (62.2%) | 97/127 (76.4%) |
| Group 2 - BSC Alone | 25/66 (37.9%) | 38/67 (56.7%) | 49/67 (73.1%) |
| Event | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone |
|---|---|---|
| Multiple organ dysfunction syndromeGeneral disorders | 14/127 | 6/67 |
| Septic shockInfections and infestations | 13/127 | 3/67 |
| Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders | 12/127 | 5/67 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 5/127 | 5/67 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 6/127 | 4/67 |
| COVID-19 pneumoniaInfections and infestations | 7/127 | 0/67 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 4/127 | 3/67 |
| Cardiac arrestCardiac disorders | 4/127 | 2/67 |
| PneumoniaInfections and infestations | 4/127 | 1/67 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 4/127 | 2/67 |
| Event | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone |
|---|---|---|
| HypotensionVascular disorders | 16/127 | 8/67 |
| Deep vein thrombosisVascular disorders | 14/127 | 2/67 |
| AnaemiaBlood and lymphatic system disorders | 13/127 | 4/67 |
| Atrial fibrillationCardiac disorders | 12/127 | 5/67 |
| PyrexiaGeneral disorders | 10/127 | 6/67 |
| HyperkalaemiaMetabolism and nutrition disorders | 8/127 | 6/67 |
| HypernatraemiaMetabolism and nutrition disorders | 11/127 | 3/67 |
| Acute kidney injuryRenal and urinary disorders | 9/127 | 5/67 |
| ConstipationGastrointestinal disorders | 5/127 | 5/67 |
| HypertensionVascular disorders | 9/127 | 3/67 |
The ITT Population consisted of all randomized participants. Participants were analyzed as randomized.
| Age, Continuous(years) | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone | Total |
|---|---|---|---|
| Mean | 63.2 ± 13.23 | 63.5 ± 12.40 | 63.3 ± 12.93 |
| Sex: Female, Male(Participants) | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone | Total |
|---|---|---|---|
| Female | 39 | 23 | 62 |
| Male | 96 | 43 | 139 |
| Race/Ethnicity, Customized(participants) | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone | Total |
|---|---|---|---|
| Not Hispanic or Latino | 100 | 46 | 146 |
| Hispanic or Latino | 27 | 11 | 38 |
| Missing/Unknown | 7 | 5 | 12 |
| Not reported | 1 | 4 | 5 |
| Race/Ethnicity, Customized(participants) | Group 1 - Ravulizumab + BSC | Group 2 - BSC Alone | Total |
|---|---|---|---|
| White | 72 | 40 | 112 |
| Black or African American | 20 | 7 | 27 |
| Missing/Unknown | 17 | 5 | 22 |
| Other | 13 | 5 | 18 |
| Asian | 9 | 6 | 15 |
| Not Reported | 4 | 2 | 6 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Supporting information: Study protocol, Clinical study report
Ran from May 2020 to primary completion in Feb 2021, 8 months.
Results were first posted in May 2022, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ravulizumab
Alexion Pharmaceuticals, Inc. →